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ABSTRACT
Background: The histiocytic sarcoma (HS) complex is a set of malignant neoplasms originating from interstitial den-
dritic cells or macrophages. When it involves macrophages of the splenic red pulp and bone marrow, it is referred to as 
hemophagocytic histiocytic sarcoma (HHS). HHS behaves more aggressively than HS and is usually fatal. HHS can be 
diagnosed by cytological and histopathological examination of neoplastic tissue. HHS is confirmed by immunohisto-
chemistry using an anti-CD11d antibody. This neoplasm is often confused with immune-mediated hemolytic anemia or 
Evans syndrome due to erythrophagocytosis and platelet consumption. The clinical presentation of the animals progresses 
with evident anemia and thrombocytopenia, leading to signs such as prostration, inappetence, and pale mucosa, making 
diagnosis challenging and often late. This study aimed to report the clinic-pathological aspects of a canine with atypical 
hemophagocytic splenic HS. 
Case: A 4-year-old male Shih-Tzu canine was referred to the Veterinary Hospital with a history of prostration and an-
orexia. Pale mucous membranes were observed on physical examination. Blood tests revealed non-regenerative anemia, 
leukopenia, and thrombocytopenia. Serum protein levels were below the reference values for the species in biochemi-
cal examinations. Hemoparasitosis was suspected; however, the result of the polymerase chain reaction was negative. 
Abdominal ultrasound revealed a splenomegaly with heterogeneous parenchyma and a slightly irregular surface, but no 
visible mass in the spleen. Due to the difficulty of stabilizing the patient, even after successive transfusions, the animal 
underwent exploratory laparotomy with medial access and posterior splenectomy. Subsequently, the spleen was surgically 
removed, fixed in 10% buffered formalin, and processed routinely. Macroscopically, it had an irregular reddish-brown 
capsular surface. Histopathological examination of the spleen revealed a densely cellular neoplasm composed of round to 
spindle cells (histiocytes) arranged haphazardly in variably sized sheets separating the pre-existing spleen stroma. These 
histopathological findings were consistent with a histiocytic malignant neoplasm. Immunohistochemical analysis was 
performed to better define the origin of the histiocytic neoplasm. Neoplastic cells showed positive immunostaining of 
more than 80% of tumor cells for the CD11d antibody and weak immunostaining for CD11c and lysozyme. The patient 
survived for less than 30 days after the first hospital visit.
Discussion: The diagnosis of HHS was based on the histological characteristics and positive immunostaining of more than 
80% of the tumor cells for the CD11d antibody. HHS is an extremely aggressive and rare tumor that affects elderly dogs 
of any breed. In this study, HHS had atypical histologic characteristics, in which erythrophagocytosis and hemosiderin 
were not observed within macrophages. HHSs arise from macrophages of the red pulp of the spleen or bone marrow and 
express the b2 integrin, CD11d, and have low expression of CD1 and CD11c, which are predominantly expressed by non-
hemophagocytic HS. The hematological and biochemical changes observed in this case were similar to those described 
in other dogs with HHS. Treatment of HHS is only palliative. Erlichia ewingii, E. canis, Anaplasma phagocytophilum, A. 
platys, Borrelia burgdorferi, Dirofilaria immitis, Leishmania infantum and immune-mediated hemolytic anemia are the 
main differential diagnoses because they cause anemia and thrombocytopenia accompanied by splenomegaly.
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INTRODUCTION
Histiocytic tumors in dogs represent a group of 
neoplasms with similar morphological characteristics 
but with different cellular origins and biological beha-
viors [3,13]. Among these tumors, histiocytic sarcomas 
(HS) are a complex of malignant neoplasms that, when 
they originate from interstitial dendritic cells, can be 
classified as localized or disseminated, depending 
on the involvement of multiple sites; if they have a 
macrophagic origin, they are called hemophagocytic 
histiocytic sarcomas (HHS) [2,8]. 
As other complex neoplasms, HHS affects 
middle-aged to elderly animals, with no predilection 
for sex [1,8], and it can affect dogs of any breed, but 
the most predisposed are the Bernese Mountain Dog, 
Rottweiler, flat-coated Retriever [5,8,12], and Minia-
ture Schnauzer [11].
HHS involves the splenic red pulp and bone 
marrow, usually without the formation of massive le-
sions at these sites and can later extend to the liver and 
lungs via the intravascular route [9]. A frequent finding 
is diffuse splenomegaly [8], which is associated with 
non-specific signs, including anorexia, weight loss, 
lethargy, and pale mucous membranes [1,8]. 
A presumptive diagnosis can be obtained by 
cytological and histopathological examinations and 
must be confirmed by immunohistochemistry [10,11]. 
No effective treatment for HHS has been established 
[3]. Currently, the same drugs adopted for the variant 
of dendritic cells are used, but HHS is associated with 
the worst prognosis of all histiocytic disorders, with a 
survival time of 1 to 2 months [6]. 
This study aimed to report the clinic-patholo-
gical aspects of a canine with atypical hemophagocytic 
splenic HS. 
CASE
A 4-year-old male Shih-Tzu, weighing 6.8 kg, 
was referred to a private Veterinary Hospital with a 
history of prostration and anorexia. The patient had an 
up-to-date vaccination history and control of endopa-
rasites and ectoparasites. In the anamnesis, the tutors 
reported that the canine had recently visited a dog hotel 
and had since presented these changes.
Physical examination revealed pale mucous 
membranes; systolic blood pressure 200 mm/Hg, me-
asured by the Doppler method; and 6.0 mmol/L lactate 
(reference value [RV]: <3.2. The other parameters were 
within the normal range for the species. The patient 
was hospitalized for complete blood count, creatinine, 
potassium, abdominal ultrasound, and investigation of 
blood parasites by polymerase chain reaction (PCR).
The hemogram showed normocytic, normo-
chromic anemia, non-regenerative anemia, mild ani-
socytosis, and polychromasia. In addition, the animal 
had hypoproteinemia (4.6 g/dL; RV: 6.0-8.0 g/dL), 
severe leukopenia (1,700 total leukocytes; RV: 6,000-
17,000 /uL), thrombocytopenia (< 20,000 /uL) plate-
lets; RV: 200,000-500,000/uL) and hypokalemia (3.3 
mmol/L; RV: 3.5-5.1 mmol/L). PCR was performed 
for Anaplasma spp., Babesia spp., Leishmania spp., 
and Rangelia vitalii, and the results were negative.
Abdominal ultrasound showed an enlarged 
spleen with convex margins, defined contours, sli-
ghtly irregular surface, normoechoic parenchyma, and 
slightly dilated lienal veins, suggesting a neoplastic 
process (Figure 1A and 1B). Due to the difficulty of 
stabilizing the patient, even after successive transfu-
sions, the animal underwent exploratory laparotomy 
with medial access and posterior splenectomy. 
Subsequently, the spleen was surgically re-
moved, fixed in 10% buffered formalin, processed 
routinely, embedded in liquid paraffin, cut at 5 µm, 
and stained with Hematoxylin and Eosin1. Macrosco-
pically, it had a reddish-brown capsular surface, was 
smooth, irregular, and averaged 21.0x7.3x1.5 cm. 
Microscopically, replacing the splenic parenchyma 
architecture was a poorly demarcated, infiltrative, 
densely cellular neoplasm composed of round to 
spindle cells (histiocytes) arranged haphazardly in 
variably sized sheets separating the pre-existing sple-
en stroma. Neoplastic cells have variably distinct cell 
borders: moderate to abundant eosinophilic, granular, 
often microvacuolated with foamy cytoplasm, and 
irregularly round to reniform nuclei with hyperchro-
matic chromatin. Anisocytosis and anisokaryosis were 
observed. The mitotic rate is variable with up to 2 per 
high-power field (2.37 mm2) [Figure 2].
Tissue samples were subjected to immunohis-
tochemistry using markers for CD32, CD52, CD102, 
CD11c2, CD11d2, CD312, CD79a2, MUM12, PAX52, 
granzyme2, and lysozyme2. This technique was perfor-
med in a private laboratory. The tested samples were 
negative for CD3, CD79a, MUM1, PAX5, CD5, CD10, 
CD 31, and granzyme but showed strong immunostai-
ning for CD11d (Figure 3A) and weak immunostaining 
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Figure 1. Ultrasonographic image of the spleen in a dog with hemophago-
cytic histiocytic sarcoma. A- Spleen with a slightly irregular surface and 
bulging margins (blue arrows). B- Dilated lienal veins (red arrow). Figure 2. Histopathology of the spleen with hemophagocytic histiocytic 
sarcoma. Infiltrative neoplastic histiocytes are obliterating spleen archi-
tecture [H&E; 40x]. 
Figure 3. Immunohistochemical analysis of the spleen with hemophagocytic histiocytic sarcoma (HHS). A- Neoplastic histiocytes show strong im-
munostaining for CD11d. B- Weak immunostaining for CD11c. C- Weak immunostaining for lysozyme. D- Approximately 30% of neoplastic cells 
immunostained for Ki67.
for CD11c (Figure 3B) and lysozyme (Figure 3C). In 
addition, approximately 30% of the neoplastic cells 
were positive for Ki67 (Figure 3D).
The patient was discharged after 7 days. Ho-
wever, 26 days after the first visit and 20 days after 
splenectomy, he returned with complications in the 
clinical picture, with 5.8 mmol/L of lactate, systolic 
blood pressure 210 mm/Hg, pale mucous membrane, 
temperature of 39.7°C, tachycardia and tachypnea, and 
died without being able to start a chemotherapy proto-
col. The owner did not allow necropsy to be performed.
DISCUSSION
The diagnosis of HHS was based on positive 
immunostaining of more than 80% of the tumor cells 
for the CD11d antibody, little staining for CD11c, and 
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hematological alterations. HHSs arise from macropha-
ges of the red pulp of the spleen or bone marrow and 
express b2 integrin, CD11d, and have low expression 
of CD1 and CD11c, which are predominantly expres-
sed by non-hemophagocytic HS in canines [9]. Further-
more, HHS must be differentiated from hepatosplenic 
T cell lymphoma, which may have similar clinical 
features and express b2 integrin [7]. In this case, the 
tumor was negative for several immunohistochemical 
markers of lymphoma.
The hematological changes observed in this 
case were similar to those described in other dogs 
with HHS [1,9,12]. Anemia and leukopenia observed 
in patients with this type of tumor are associated with 
the activity of mutated macrophages, which perform 
phagocytosis in lymphoid organs, and the absence of 
regeneration can be explained by the infiltration of 
neoplastic histiocytes into the bone marrow [8,9]; ho-
wever, it was not possible to perform the myelogram to 
confirm this hypothesis. Thrombocytopenia is probably 
derived from multiple causes, including consumption 
and phagocytosis by neoplastic macrophages. Other 
causes of anemia and thrombocytopenia accompa-
nied by splenomegaly, such as hemoparasitosis and 
immune-mediated hemolytic diseases, were ruled out. 
Erlichia ewingii, E. canis, Anaplasma phagocytophi-
lum, A. platys, Borrelia burgdorferi, Dirofilaria im-
mitis, Leishmania infantum, and IMHA are the main 
differential diagnoses [8-10]. 
Marked hypoproteinemia and hypokalemia were 
observed in this case. Biochemical alterations can be 
observed in dogs with HHS, mainly hypoalbuminemia, 
hypercholesterolemia, and hypoproteinemia, secondary to 
the inflammatory process induced by the neoplasm, since 
they are negative acute phase proteins [1,9,12]. 
In this study, the histological atypicality of 
the splenic tumor was noteworthy, in which erythro-
phagocytosis and hemosiderin were not observed 
inside macrophages. The histologic characteristics 
described in HHS generally present marked erythro-
phagocytosis and histiocytes containing large deposits 
of hemosiderin [4,9]. The other histological changes 
observed in this case suggest the diagnosis of HS, but 
the confirmatory diagnosis can only be made through 
immunophenotypic characterization of the tumor [3,8].
HHS, in this case, occurred in a 4-year-old 
Shih-Tzu. Although there are few reports of this neo-
plasm, in 2 studies, HHS occurred in elderly Rottweiler 
dogs [5,12].
HHS is among the histiocytic disorders with 
the worst prognosis due to their aggressive biological 
behavior and non-specific clinical manifestations that 
hinder early diagnosis [7,8]. The patient in this report 
had a survival of 26 days from the first visit, which 
corroborates the reported survival rates ranging from 
days to 1 or 2 months, regardless of therapy [3,4,6], 
which is usually palliative due to the rapid evolution 
of the tumor.
In conclusion, HHS is a rare and poorly descri-
bed neoplasm in dogs with clinical signs and unspecific 
hematological alterations. Despite racial predisposi-
tion, dogs of any breed can develop tumors. HHS has 
an aggressive biological behavior, and treatment is 
only palliative.
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e Inovação do Espírito Santo - FAPES.
Declaration of interest. The authors report no conflict of in-
terest. The authors alone were responsible for the content and 
writing of paper.
REFERENCES
1 Abadie J., Hédan B., Cadieu E., De Brito C., Devauchelle P., Bourgain C., Parker H. G., Vaysse A., Margaritte-
Jeannin P., Galibert F., Ostrander E. A. & André C. 2009. Epidemiology, pathology, and genetics of histiocytic 
sarcoma in the Bernese mountain dog breed. The Journal of Heredity. 100(1): 19-27.
2 Affolter V.K. & Moore P.F. 2002. Localized and Disseminated Histiocytic Sarcoma of Dendritic Cell Origin in 
Dogs. Veterinary Pathology. 39(1): 74-83. 
3 Clifford C.A., Skorupski K.A. & Moore P.F. 2020. Histiocytic Diseases. In: Vail D.M., Thamm D.H. & Liptak J.M. 
(Eds). Small Animal Clinical Oncology. 6th edn. St. Louis: Elsevier, pp.791-810.
5
                                                                                                           H. Stein, M.P. Oliveira, C.S. Lasta, et al. 2021. Atypical Spleen Hemophagocytic Histiocytic Sarcoma in a Dog.                                                                       
                                                                                                                               Acta Scientiae Veterinariae. 49(Suppl 1): 717.
CR717
http://seer.ufrgs.br/ActaScientiaeVeterinariae
4 Dervisis N.G., Kiupel M., Qin Q. & Cesario L. 2017. Clinical prognostic factors in canine histiocytic sarcoma. Vet-
erinary and Comparative Oncology. 15(4): 1171-1180. 
5 Goulart J. C., Sanches F.J., Merlini N.B., Mazzucatto B.C., Gasser B. & Marcusso P.F. 2020.  Hemophagocytic 
Histiocytic Sarcoma in Dog. Acta Scientiae Veterinariae. 48(1): 574-580.
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